

# HRT Treatment Selector

Charts revised February 2019. Full information available at [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org)

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

	ATV/c	ATV/r	DRV/c	DRV/r	LPV/r	DOR	EFV	ETV	NVP	RPV	MVC	BIC/ F/TAF	DTG	EVG/c/ F/TAF	EVG/c/ F/TDF	RAL	FTC or 3TC	F/TAF	TDF	ZDV
<b>Estrogens</b>																				
Estradiol	↑ <sup>a</sup>	↓ <sup>b</sup>	↑ <sup>a</sup>	↓ <sup>b</sup>	↓ <sup>b</sup>	↔	↓ <sup>b</sup>	↓ <sup>b</sup>	↓ <sup>b</sup>	↔	↔	↔	↔	↔	↑ <sup>a</sup>	↑ <sup>a</sup>	↔	↔	↔	↔
<b>Progestins (HRT)</b>																				
Drospirenone	↑ <sup>a,c</sup>	↑ <sup>a</sup>	↑ <sup>a</sup>	↑ <sup>a</sup>	↑ <sup>a</sup>	↔	↓ <sup>b</sup>	↓ <sup>b</sup>	↓ <sup>b</sup>	↔	↔	↔	↔	↔	↑ <sup>a</sup>	↑ <sup>a</sup>	↔	↔	↔	↔
Dydrogesterone	↑ <sup>a</sup>	↑ <sup>a</sup>	↑ <sup>a</sup>	↑ <sup>a</sup>	↑ <sup>a</sup>	↔	↓ <sup>b</sup>	↓ <sup>b</sup>	↓ <sup>b</sup>	↔	↔	↔	↔	↔	↑ <sup>a</sup>	↑ <sup>a</sup>	↔	↔	↔	↔
Levonorgestrel	↑ <sup>a</sup>	↑ <sup>a</sup>	↑ <sup>a</sup>	↑ <sup>a</sup>	↑ <sup>a</sup>	↔	↓ <sup>b</sup>	↓ <sup>b</sup>	↓ <sup>b</sup>	↔	↔	↔	↔	↔	↑ <sup>a</sup>	↑ <sup>a</sup>	↔	↔	↔	↔
Medroxy-progesterone (oral)	↑ <sup>a</sup>	↑ <sup>a</sup>	↑ <sup>a</sup>	↑ <sup>a</sup>	↑ <sup>a</sup>	↔	↓ <sup>b</sup>	↓ <sup>b</sup>	↓ <sup>b</sup>	↔	↔	↔	↔	↔	↑ <sup>a</sup>	↑ <sup>a</sup>	↔	↔	↔	↔
Norethisterone (Norethindrone)	↑ <sup>a</sup>	↑ <sup>a</sup>	↑ <sup>a</sup>	↑ <sup>a</sup>	↑ <sup>a</sup>	↔	↓ <sup>b</sup>	↓ <sup>b</sup>	↓ <sup>b</sup>	↔	↔	↔	↔	↔	↑ <sup>a</sup>	↑ <sup>a</sup>	↔	↔	↔	↔
Norgestrel	↑ <sup>a</sup>	↑ <sup>a</sup>	↑ <sup>a</sup>	↑ <sup>a</sup>	↑ <sup>a</sup>	↔	↓ <sup>b</sup>	↓ <sup>b</sup>	↓ <sup>b</sup>	↔	↔	↔	↔	↔	↑ <sup>a</sup>	↑ <sup>a</sup>	↔	↔	↔	↔

**Colour Legend**

- No clinically significant interaction expected.
- These drugs should not be coadministered.
- Potential interaction which may require a dose adjustment or close monitoring.
- Potential interaction predicted to be of weak intensity. No *a priori* dosage adjustment is recommended.

**Text Legend**

- ↑ Potential increased exposure of the hormone
- ↓ Potential decreased exposure of the hormone
- ↔ No significant effect

**Notes**

- a The clinical significance of increased exposure in terms of overall risk of deep vein thrombosis, pulmonary embolism, stroke and myocardial infarction in postmenopausal women receiving substitution hormones is unknown.
- b Monitor for signs of estrogen deficiency.
- c Coadministration is contraindicated in the US product label due to the potential for hyperkalaemia. The European product label recommends clinical monitoring for hyperkalaemia.